Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats

Kebapçılar, Ayşe Gül; İlhan, Tolgay Tuyan; Dursunoğlu, Duygu; Kebapçılar, Levent; İpekçi, Süleyman Hilmi; Baldane, Süleyman; Uçar, Mustafa Gazi; Kıraç, Cem Onur; Kurt, Kübra; Çelık, Çetin

doi:10.1080/09513590.2017.1320384

Cited by 7 publications

(5 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, according to Ricci et al, Bevacizumab significantly inhibited cell proliferation in lesions, reduced vascular density and increased the apoptotic cell percentage (16). Also, Kebapcilar et al showed higher reduction for the glandular epithelium and uterine vessels compared to controls treated with progesterone (18). Interestingly, Bevacizumab treatment did not affect ovarian reserve assessed by follicle quantification at histochemistry of ovarian serial sections (21).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report

et al. 2021

View full text Add to dashboard Cite

Angiogenesis plays a pivotal role in implantation and development of ectopic endometrial lesions. Thus, the potential usefulness of anti-angiogenic therapies has been speculated. Several reports describe their usefulness in animal models. Nonetheless this therapy has not been tested on humans yet. Here we report the outcome of a patient treated for a severe endometriosis with Bevacizumab (Avastin®), a monoclonal antibody directed against the vascular endothelial growth (VEGF). After a first-look laparoscopy with confirmatory biopsies was performed, three doses of Bevacizumab at 2-week intervals were administered. The therapy showed a well-tolerated profile and the prompt disappearance of the therapy-refractory chronic dysmenorrhea. A suppression of metabolic activity at the PET-scan compared to the basal one performed at diagnosis was also recorded. Furthermore, compared to the diagnostic biopsies prior the treatment, we documented a shift in the hormonal receptors profile toward a higher expression of progesterone and estrogen receptors in the endometriotic lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Animal experiments already showed beneficial effects both in the treatment and prophylaxis of endometriosis relapse (16)(17)(18)(19)(20)(21). The effect of vascular endothelial growth factor inhibition on the volume of endometrial implants was described by all these authors.…”

Section: Discussionmentioning

confidence: 99%

Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Endometriosis progression relies heavily on angiogenesis. Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor (VEGF), resulted in larger regression of endometriotic implants than DNG when injected along with oral rosuvastatin in mice [142] . Preclinical studies have shown the effects of various tyrosine kinase inhibitors.…”

Section: Investigational Therapeutic Optionsmentioning

confidence: 99%

Medical treatments of endometriosis: a review

Elbasueny

Geerts

Yang

et al. 2022

Reproductive and Developmental Medicine

View full text Add to dashboard Cite

Endometriosis is a chronic gynecological disorder that affects approximately 10% of women of reproductive age. Most medical treatments used today for endometriosis pain are hormonal therapies, which are not an option for those trying to conceive and are not tolerated by a subset of patients due to side effects. In this article, we offer a comprehensive review of current and investigational medical therapeutic options used to treat endometriosis pain, as well as a symptom-based systematic approach for patients with painful endometriosis. We have also included recommendations for research to enhance the evolution of novel therapeutic options. A thorough literature search was carried out, and the data were synthesized using a synthesis matrix that classifies and categorizes various arguments.

show abstract

“…It has been found that bevacizumab suppresses endometriotic implants and prevents their progression in rat models of endometriosis without affecting the ovarian reserve, and furthermore, its efficacy is comparable to GnRH-a and higher than oral progesterone compounds. 71,93,94 Moreover, it reduces vascular density and peritoneal fluid VEGF concentration. 95 However, administration of bevacizumab carries a high risk of severe adverse effects (gastrointestinal perforation, thrombosis, severe bleeding, impaired kidney function, and wound healing), which are unlikely to be acceptable from patients with a nonmalignant disease.…”

Section: Anti-vegf Moleculesmentioning

confidence: 99%

“…Recent animal studies have also explored whether bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody that is widely used in colorectal cancer, could be used against endometriosis due to its antiangiogenic features. It has been found that bevacizumab suppresses endometriotic implants and prevents their progression in rat models of endometriosis without affecting the ovarian reserve, and furthermore, its efficacy is comparable to GnRH-a and higher than oral progesterone compounds 71,93,94 . Moreover, it reduces vascular density and peritoneal fluid VEGF concentration 95 .…”

Section: Novel Antiangiogenic Agents For Management Of Women With End...mentioning

confidence: 99%

The Effect of Novel Medical Nonhormonal Treatments on the Angiogenesis of Endometriotic Lesions

Thanatsis¹,

Filindris²,

Siampalis³

et al. 2021

Obstetrical &Amp; Gynecological Survey

View full text Add to dashboard Cite

Importance: Irrespective of the precise mechanisms leading to endometriosis, angiogenesis is essential for the establishment and long-term proliferation of the disease. As current surgical and medical management options for women with endometriosis have substantial drawbacks and limitations, novel agents are needed and molecules targeting the angiogenic cascade could serve as potential candidates.Objective: Our aim was to review current data about the role of angiogenesis in the pathophysiology of endometriosis and summarize the novel antiangiogenic agents that could be potentially used in clinical management of patients with endometriosis.Evidence Acquisition: Original research and review articles were retrieved through a computerized literature search.Results: Loss of balance between angiogenic activators and suppressors triggers the nonphysiological angiogenesis observed in endometriotic lesions. Several proangiogenic mediators have been identified and most of them have demonstrated increased concentrations in the peritoneal fluid and/or serum of women with endometriosis. Among the antiangiogenic molecules, anti-vascular endothelial growth factor agents, dopamine agonists, romidepsin, and statins have shown the most promising results so far.Conclusions and Relevance: Given the limitations of current treatments of endometriosis, there is a need for novel, more efficient agents. Antiangiogenic molecules could be used potentially in clinical management of women with endometriosis; however, their safety and efficiency should be carefully assessed prior to that. Further large prospective trials in humans are needed before any treatment is introduced into daily clinical practice.Target Audience: Obstetricians and gynecologists, family physicians Learning Objectives: After participating in this activity, physicians should be better able to summarize current knowledge about the role of proangiogenic and antiangiogenic mediators in the development of endometriosis; outline the main antiangiogenic agents that are under investigation; and describe their effect on the angiogenic mediators of endometriosis.Endometriosis is a benign disorder characterized by the presence of endometrial tissue (glandular epithelium and stroma) outside the uterine cavity, mainly in the pelvic peritoneum, the ovaries, the torus uterinus, the uterosacral ligaments, and the rectovaginal septum. 1 This functional endometrial tissue triggers a chronic inflammatory response, resulting in peritoneal fibrosis, formation of adhesions, and, subsequently, development of chronic pelvic All authors, faculty, and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations relevant to this educational activity.

show abstract

Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats

Cited by 7 publications

References 32 publications

Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report

Antiangiogenic Therapy as a New Strategy in the Treatment of Endometriosis? The First Case Report

Medical treatments of endometriosis: a review

The Effect of Novel Medical Nonhormonal Treatments on the Angiogenesis of Endometriotic Lesions

Contact Info

Product

Resources

About